USANA Health Sciences, Inc. (NYSE:USNA) CFO G Doug Iiekking Sells 5,198 Shares

USANA Health Sciences, Inc. (NYSE:USNA) CFO G Doug Iiekking sold 5,198 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total transaction of $232,662.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

USANA Health Sciences Price Performance

Shares of NYSE:USNA opened at $45.07 on Thursday. The firm’s 50 day simple moving average is $46.42 and its two-hundred day simple moving average is $48.05. The company has a market capitalization of $865.34 million, a P/E ratio of 14.04, a P/E/G ratio of 1.38 and a beta of 0.94. USANA Health Sciences, Inc. has a 1-year low of $41.45 and a 1-year high of $69.60.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.35. The company had revenue of $221.08 million during the quarter, compared to the consensus estimate of $206.70 million. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On USANA Health Sciences

Several large investors have recently made changes to their positions in USNA. State Board of Administration of Florida Retirement System grew its position in shares of USANA Health Sciences by 22.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock worth $409,000 after purchasing an additional 1,560 shares in the last quarter. Pzena Investment Management LLC boosted its stake in USANA Health Sciences by 3.1% in the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after purchasing an additional 23,729 shares during the period. BNP Paribas Financial Markets grew its holdings in USANA Health Sciences by 18.1% during the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock valued at $1,883,000 after buying an additional 5,952 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of USANA Health Sciences by 58.9% during the first quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company’s stock valued at $3,987,000 after buying an additional 30,485 shares during the last quarter. Finally, DGS Capital Management LLC lifted its holdings in shares of USANA Health Sciences by 61.8% in the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock worth $352,000 after buying an additional 2,773 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

USNA has been the subject of several analyst reports. DA Davidson reduced their price objective on USANA Health Sciences from $48.00 to $46.00 and set a “neutral” rating for the company in a research note on Tuesday. StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 12th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.